Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative pharmaceutical products aimed at treating various human diseases in areas such as immunology, metabolism, cardiology, and ophthalmology. Its pipeline includes drug candidates like LX1031, which has completed Phase II trials for irritable bowel syndrome, and LX4211, also in Phase II for type 2 diabetes. Other candidates include LX2931, currently in Phase II trials for rheumatoid arthritis, and LX1032, which has completed Phase II for carcinoid syndrome symptoms. The company is also advancing LX7101, a preclinical candidate for glaucoma. Lexicon has formed strategic alliances with several major pharmaceutical companies, including Bristol-Myers Squibb and Takeda Pharmaceutical, as well as collaborations for drug development and discovery.

Lonnel Coats

President and CEO

Matthew Cullen

Vice President-Value and Access

Mike Exton

CEO

Tom Garner

Senior Vice President and Chief Commercial Officer

1 past transactions

Coelacanth

Acquisition in 2001
Coelacanth, which uses proprietary chemistry technologies to rapidly discover new chemical entities for drug development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.